Fig. 2

in vitro HIV-1 infection of macrophages following treatment with A2ti, anti-A2 antibody, or maraviroc. a Structures and reported IC₅₀ values of the three triazole-based A2ti tested [13]. b Macrophages were treated with different A2ti (25 or 50 μM), an anti-A2 antibody (25 μg/mL), or maraviroc (25 μg/mL) prior to exposure to HIV-1_JR-CSF (MOI = 1). After 24 h, the supernatants were collected and the relative amount of the HIV-1 capsid protein p24 (pg/mL) was measured via ELISA. Controls included uninfected, HIV only, heat-inactivated virus (H.I. HIV), and DMSO at a concentration matched to that of 50 μM A2ti. Data are presented as the means ± SD of three independent experiments. **p < 0.01 and ***p < 0.001 as determined by unpaired two-tailed Student’s t-tests compared to the HIV only group. c HaCaT cells were left untreated or treated with 50 μM A2ti-1. The following day cells were infected with GFP-plasmid-containing HPV16 pseudovirions (PsV). GFP-positive cells were measured after 48 h by flow cytometry. The mean percentage ± SD of infected cells normalized to the untreated group from a representative experiment performed in triplicate is presented. **p < 0.01 as determined by unpaired two-tailed Student’s t-test compared to the untreated group